Stereotaxis Q2 revenue misses estimates, dragged by system decline
STXS•Analyst coverage and valuation
The current average analyst rating on the shares is buy, with 4 strong buy or buy ratings, no hold ratings, and no sell or strong sell ratings.
Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 177.8% above its August 10 closing price of $1.44.
Outlook for 2026 and profitability
The company expects recurring revenue to reach $7 million in Q3 and $8 million in Q4 2026. It projects system revenue of about $3 million in both Q3 and Q4 2026.
Stereotaxis said it anticipates reaching cash flow profitability in the first half of 2027.
Recurring revenue and acquisition updates
Recurring revenue increased due to contributions from new robotic catheters, despite procedural pressure from limited catheter supply.
Stereotaxis also completed its previously announced Robocath acquisition, saying the deal expands its endovascular technology portfolio and is intended to strengthen its robotic technology leadership across endovascular procedures.
